Largest biotech by total assets
Everything the company owns, as its balance sheet stood at the end of the latest fiscal year.
Amgen leads the 24 biotech ranked by total assets, at DKK 616.9B, ahead of Gilead Sciences (DKK 401.9B) and Biogen (DKK 200.5B). Figures as of 18 Nov 2026, 14:51 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenDKK 616.9B
- Median
- DKK 17.4B
- Combined market value
- DKK 5.73T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Total assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | DKK 616.9B | DKK 1.66T | DKK 3,060.94 | 1.85% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | DKK 401.9B | DKK 1.43T | DKK 1,151.63 | 0.68% down | 33% up | ||
| 3 | BiogenBIIB · Health Care | DKK 200.5B | DKK 252.2B | DKK 1,706.23 | 0.10% down | 49% up | ||
| 4 | BioNTechBNTX · Health Care | DKK 166.1B | DKK 143B | DKK 576.73 | 0.20% down | 16% down | ||
| 5 | ModernaMRNA · Health Care | DKK 84B | DKK 558B | DKK 1,379.05 | 2.08% down | 755% up | ||
| 6 | argenxARGX · Health Care | DKK 59.1B | DKK 410.1B | DKK 6,521.89 | 1.07% up | 4% up | ||
| 7 | QiagenQGEN · Health Care | DKK 42.8B | DKK 69.9B | DKK 338.35 | 0.13% down | 12% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | DKK 31.5B | DKK 113.5B | DKK 1,121.73 | 0.72% down | 20% up | ||
| 9 | VaxcytePCVX · Health Care | DKK 20.4B | DKK 63.3B | DKK 400.08 | 1.09% down | 22% up | ||
| 10 | RepligenRGEN · Health Care | DKK 20.1B | DKK 74.1B | DKK 1,159.63 | 5.00% up | 5% up | ||
| 11 | ExelixisEXEL · Health Care | DKK 19.4B | DKK 113.9B | DKK 466.89 | 0.09% up | 63% up | ||
| 12 | Bio-TechneTECH · Health Care | DKK 17.6B | DKK 77.8B | DKK 495.29 | 0.14% up | 26% up | ||
| 13 | Halozyme TherapeuticsHALO · Health Care | DKK 17.2B | DKK 74.4B | DKK 652.70 | 0.13% down | 37% up | ||
| 14 | Revolution MedicinesRVMD · Health Care | DKK 16B | DKK 233.6B | DKK 1,080.02 | 2.52% down | 131% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | DKK 15.4B | DKK 27.3B | DKK 281.80 | 3.06% up | 21% down | ||
| 16 | Kymera TherapeuticsKYMR · Health Care | DKK 11.9B | DKK 70.8B | DKK 829.59 | 0.25% up | 87% up | ||
| 17 | Krystal BiotechKRYS · Health Care | DKK 9.1B | DKK 61.2B | DKK 2,063.99 | 1.52% up | 46% up | ||
| 18 | ImmunovantIMVT · Health Care | DKK 6.5B | DKK 47B | DKK 227.01 | 0.38% up | 43% up | ||
| 19 | CG OncologyCGON · Health Care | DKK 5.4B | DKK 47.5B | DKK 531.55 | 1.12% down | 85% up | ||
| 20 | Twist BioscienceTWST · Health Care | DKK 4.4B | DKK 52.6B | DKK 771.84 | 1.20% up | 340% up | ||
| 21 | Adaptive BiotechnologiesADPT · Health Care | DKK 3.5B | DKK 31.3B | DKK 193.33 | 0.35% down | 88% up | ||
| 22 | ImmunityBioIBRX · Health Care | DKK 3.4B | DKK 44.6B | DKK 41.88 | 1.76% down | 193% up | ||
| 23 | Scholar Rock HoldingSRRK · Health Care | DKK 2.8B | DKK 39.1B | DKK 320.58 | 4.43% up | 14% up | ||
| 24 | Kodiak SciencesKOD · Health Care | DKK 2.4B | DKK 42.9B | DKK 656.48 | 0.41% down | 396% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 6.8099 DKK).
Questions and answers
Which biotech rank first by total assets?
Amgen (DKK 616.9B), Gilead Sciences (DKK 401.9B) and Biogen (DKK 200.5B) are the top three of the 24 biotech ranked by total assets as of 18 Nov 2026, 14:51 UTC.
How many biotech are in this ranking?
24 are ranked by total assets.
What are these biotech worth together?
The 24 biotech ranked by total assets have a combined market value of DKK 5.73T as of 18 Nov 2026, 14:51 UTC.
What does ranking by total assets measure?
Everything the company owns, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech by total assets”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=total-assets
Underlying data: Yahoo Finance; SEC EDGAR.